Sign in
Taking peopleNo phase

Ergometrine or carbetocin injections to reduce bleeding in surgery for uterine fibroids

Compares ergometrine and carbetocin injected into the uterus to reduce bleeding in fibroid surgery.

Key facts

Who runs it
Cairo University
Where
Egypt1 site in 1 countryChoose a country to see its sites
Trial code
Registry title
Ergometrine Versus Carbetocin to Decrease Blood Loss in Myomectomy
Status
Recruiting
People taking part
40 people, planned
Started
18 Jan 2026
Planned end
30 Aug 2026
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Methylergometrine (Intramyometrial Injection)
  • Carbetocin (Intramyometrial Injection)
Record updated
5 February 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for women with uterine fibroids that cause symptoms, who are planned to have the fibroids removed through an open abdominal operation. It compares two drugs injected into the womb muscle to reduce bleeding.

Age
25 to 48 years
Sex
Women only
Disease stage
Fibroids inside the womb wall, FIGO types 3 to 6, seen on ultrasound or MRI. They cause symptoms such as abnormal bleeding, pelvic pain or pressure and need surgery. The largest fibroid is at most 20 cm (7.9 in). Body mass index (BMI) below 35 kg/m².
Earlier treatment
No earlier surgery on the womb. No hormone treatment in the 3 months before joining.

Main reasons for not taking part

  • Fibroids of FIGO type 0, 1, 2, 7 or 8, or a past pelvic or abdominal infection
  • High blood pressure, heart or lung disease, diabetes or other long-term hormone or metabolic disease, kidney or liver problems
  • Allergy to methylergometrine or carbetocin
  • Bleeding disorders, use of blood thinners or antiplatelet drugs, or hemoglobin below 10 g/dL
  • BMI of 35 kg/m² or more, or the operation changed to removal of the womb

The registry criteria, word for word

Show all 23 criteriaShow less

Who can take part

  • Female participants aged 25 to 48 years
  • Body mass index (BMI) < 35 kg/m²
  • Symptomatic uterine fibroids requiring surgical management (e.g., abnormal uterine bleeding, pelvic pain, or pressure symptoms)
  • Intramyometrial uterine myomas classified as FIGO types 3 to 6, diagnosed by transvaginal ultrasonography or magnetic resonance imaging
  • Maximum diameter of the largest myoma ≤ 20 cm
  • Eligible for and scheduled to undergo abdominal myomectomy
  • Able and willing to provide written informed consent

Who cannot take part

  • History of prior uterine surgery
  • Use of hormonal treatment within 3 months prior to enrollment
  • Current use of antiplatelet or anticoagulant therapy
  • History of pelvic inflammatory disease, peritonitis, or significant abdominal or pelvic infection
  • Known drug allergy
  • Hypertension
  • Cardiac or pulmonary disease
  • Chronic endocrine or metabolic disease (e.g., diabetes mellitus)
  • Renal or hepatic impairment
  • High risk of bleeding, including:
  • Known bleeding disorders
  • Preoperative anemia (hemoglobin < 10 g/dL)
  • FIGO type 0, 1, 2, 7, or 8 myomas (intracavitary, submucosal, pedunculated subserosal, cervical, or adnexal)
  • Contraindication to methylergometrine or carbetocin, including:
  • BMI ≥ 35 kg/m²
  • Intraoperative conversion from myomectomy to hysterectomy

The main criteria, as questions

These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Are you between 25 and 48 years old?

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The goal of this randomized clinical trial is to determine whether intramyometrial ergometrine injection or intramyometrial carbetocin injection is more effective in reducing blood loss during and after abdominal myomectomy in women undergoing surgery for symptomatic uterine fibroids.

Read full original descriptionShow less

The main questions it aims to answer are:

Does intramyometrial ergometrine reduce intraoperative and postoperative blood loss during abdominal myomectomy?

Does intramyometrial carbetocin reduce intraoperative and postoperative blood loss during abdominal myomectomy?

Is there a difference between the two drugs in the need for blood transfusion and postoperative hemoglobin drop?

Researchers will compare intramyometrial ergometrine injection with intramyometrial carbetocin injection to see which intervention is more effective in controlling surgical bleeding and improving surgical outcomes.

Participants will:

Undergo abdominal myomectomy for uterine fibroids

Receive either intramyometrial ergometrine or intramyometrial carbetocin during surgery

Be monitored for intraoperative blood loss, postoperative blood loss, hemoglobin changes, and need for blood transfusion

The 2 groups in the trial

  • Intramyometrial Ergometrine InjectionExisting treatment, for comparison

    Participants receive intramyometrial injection of methylergometrine maleate diluted in saline and administered circumferentially around the myoma before uterine incision during abdominal myomectomy.

    Treatment: Methylergometrine (Intramyometrial Injection)

  • Intramyometrial Carbetocin InjectionTreatment being tested

    Participants receive intramyometrial injection of carbetocin diluted in saline and administered circumferentially around the myoma before uterine incision during abdominal myomectomy.

    Treatment: Carbetocin (Intramyometrial Injection)

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Intramyometrial Ergometrine Injection Versus Intramyometrial Carbetocin Injection to Decrease Blood Loss During and After Abdominal Myomectomy: A Randomized Clinical Trial
Plain-language title
Ergometrine or carbetocin injections to reduce bleeding in surgery for uterine fibroidsGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 15 November 2026.
Criteria questions
Built from NCT07390864, who can take part
Record updated
5 February 2026